IMCR — Immunocore Holdings Ltd
NASDAQ · Healthcare · Biotechnology
$36.63
-$0.23 (-0.61%)
Immunocore Holdings Ltd (IMCR) is a biotechnology company listed on NASDAQ. It is led by Bahija Jallal Ph.D., based in 92 Park Drive, Abingdon, United Kingdom, OX14 4RY, with about 524 employees. Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Latest reported IMCR revenue for 2025-09-30 was $103.7M. Net income was -$177.0K. Revenue was up 5.8% from 2025-06-30 to 2025-09-30. IMCR currently screens at market cap $1.45B.
Use this IMCR page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the IMCR quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the IMCR SEC filings page. Lician reads the product cache first so this HTML stays unique to Immunocore Holdings Ltd even when a live quote feed is slow.
About Immunocore Holdings Ltd
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
IMCR Key Statistics
Market Cap
$1.45B
Volume
255,133
Previous Close
$37.40
Day Range
$36.70 – $37.25
P/B Ratio
3.69
EPS
-$1.02
Revenue
$310.20M
Net Income
-$51.09M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+24.4%
Profit Margin
-16.5%
Employees
524
IMCR Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $310.20M | $249.43M | $174.36M | $36.48M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$51.09M | -$55.29M | -$52.54M | -$180.03M |
| EPS (Diluted) | -$1.02 | -$1.13 | -$1.15 | -$4.24 |
Total Assets
$1.01B
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$455.73M
Operating Cash Flow
$26.06M
Free Cash Flow
$0.00
Immunocore Holdings Ltd Company Information
- CEO & Executive Director
- Bahija Jallal Ph.D.
- Headquarters
- 92 Park Drive, Abingdon, United Kingdom, OX14 4RY
- Website
- www.immunocore.com
- Phone
- 44 12 3543 8600
- IPO / Founded
- 2021-02-05
- Sector
- Healthcare
- Industry
- Biotechnology